Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

NCT ID: NCT04528056

Last Updated: 2020-08-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-01
• Study Completion Date: 2022-10-31

Brief Summary

Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.

Detailed Description

Pulmonary arterial hypertension is characterized by decompensated increase of pulmonary artery pressure owing to continuous progression of pulmonary vascular resistance and can ultimately cause right heart failure even death. At present, the treatment of pulmonary arterial hypertension is mainly the application of specific drug therapy. Specific drug therapy involves the three major pathways of endothelin, nitric oxide and prostacyclin. The main mechanisms of vasodilation and anti-proliferation are used to treat pulmonary arterial hypertension. However, the price of specific drug therapy is too expensive, which puts huge financial pressure on patients. Evidence shows that inflammation exists in the early stages of pulmonary arterial hypertension and anti-inflammatory treatment is effective in animal experiments. Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.

Conditions

Pulmonary Arterial Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ambrisentan+Sulfasalazine

Group Type: EXPERIMENTAL

Sulfasalazine

Intervention Type: DRUG

Sulfasalazine is an anti-inflammatory and immunosuppressive drug

Ambrisentan

Intervention Type: DRUG

Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension

Ambrisentan+Sulfasalazine's placebo

Group Type: ACTIVE_COMPARATOR

Ambrisentan

Intervention Type: DRUG

Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension

Sulfasalazine's placebo

Intervention Type: DRUG

Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage

Ambrisentan's placebo+Sulfasalazine

Group Type: EXPERIMENTAL

Sulfasalazine

Intervention Type: DRUG

Sulfasalazine is an anti-inflammatory and immunosuppressive drug

Ambrisentan's placebo

Intervention Type: DRUG

Ambrisentan's placebo is similar to Ambrisentan in form and dosage

Ambrisentan's placebo+Sulfasalazine's placebo

Group Type: PLACEBO_COMPARATOR

Sulfasalazine's placebo

Intervention Type: DRUG

Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage

Ambrisentan's placebo

Intervention Type: DRUG

Ambrisentan's placebo is similar to Ambrisentan in form and dosage

Interventions

Sulfasalazine

Sulfasalazine is an anti-inflammatory and immunosuppressive drug

Intervention Type: DRUG

Ambrisentan

Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension

Intervention Type: DRUG

Sulfasalazine's placebo

Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage

Intervention Type: DRUG

Ambrisentan's placebo

Ambrisentan's placebo is similar to Ambrisentan in form and dosage

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Pulmonary artery systolic pressure estimated in the most recent echocardiography examination before screening ≧40mmHg.

2. Before the study, subjects received the best traditional pulmonary arterial hypertension(PAH) treatment (such as oral Ca2+ antagonists, oxygen therapy, digoxin, diuretics, and anticoagulants), and no increase, discontinuation, or dose change at least one month before randomization. But it is allowed to stop or adjust anticoagulants, and adjust the therapeutic dose of diuretics.

3. The results of echocardiography showed that the systolic and diastolic functions of the left ventricle were normal, and there was no clinically significant left heart disease (such as mitral valve disease).

Exclusion Criteria

1. Patients who have received endothelin receptor antagonists and anti-inflammatory drugs within 30 days before randomization.

2. Patients with changes in the basic PAH treatment within one month before randomization (such as addition/removal of therapeutic drugs or dose adjustment; including but not limited to oxygen, diuretics, digoxin, anticoagulants, immunosuppressants, or Ca2+ antagonists ). But we allows the discontinuation of anticoagulants or change the dose and the change of diuretic dose.

3. Patients who diagnosed with other etiology of PAH, such as portal hypertension, pulmonary vein occlusive disease, etc.

4. Patients who have a history of left heart disease including ischemic heart disease, myocardial infarction, symptomatic coronary artery disease; or trans-channel radionuclide angiography, angiography, or echocardiography as assessed by mean pulmonary capillary wedge pressure (or left ventricular end diastolic volume) ≥ 15 mmHg or left ventricular ejection fraction ≤ 40%; or systemic hypertension that cannot be effectively controlled, systolic blood pressure> 160 mmHg or diastolic blood pressure> 100 mmHg.

5. Patients who have a history of lung diseases, including chronic obstructive pulmonary disease, interstitial lung disease, etc.

6. Patients who have a history of blood diseases, including a history of coagulation disorders within 6 months before screening.

7. Patients who are allergic to two or more drugs or food; or are known to be allergic to one anti-inflammatory drug (steroidal or non-steroidal anti-inflammatory drug).

8. Liver function test exceeds or equals 3 times the upper limit of normal or suffering from known Child-Pugh Class C liver disease.

9. Patients with chronic renal insufficiency, and the screening creatinine value is greater than 2.5mg/dL (221μmol/L) or need dialysis.

10. Patients with other diseases or conditions that can affect the results of the research.

11. Patients who participated in other study drugs or medical devices within 30 days before screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RenJi Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jieyan Shen, PhD

Role: STUDY_CHAIR

Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Locations

Renji Hospital

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Jieyan Shen, PhD

Role: CONTACT

shenjieyan@renji.com

+8613701864819

Facility Contacts

Jian Wang, postgraduate

Role: primary

wangjian_ky@163.com

+8613780172992

Other Identifiers

treatment of PAH

Identifier Type: -

Identifier Source: org_study_id